Kornimate/medical-research-clean huggingface dataset:
endobronchial ultrasound-guided transbronchial needle aspiration for lymph node staging in patients with non-small cell lung cancer pursuing stereotactic body radiotherapy (sbrt)

Conditions: Lung Cancer

Summary: it is reported that more than 90,000 patients died of lung cancer and more than 20% of them were older than 80 years in north america. therefore a less invasive but effective treatment is required for patients with lung cancer of advanced age, diminished pulmonary functions, and chronic diseases. stereotactic body radiation therapy (sbrt) is an effective and well-tolerated treatment for early stage lung cancer in medically inoperable patients. on the other hand, accurate mediastinal and hilar lymph node staging is one of the most important factors that determine the outcome and indications for sbrt. endobronchial ultrasound-guided transbronchial needle aspiration (ebus-tbna) is a novel, minimally invasive modality that enables the assessment of mediastinal and hilar lymph nodes with a high sensitivity. accurate lymph node staging by ebus-tbna will allow opportunities for high-risk patients with lung cancer to undergo minimally invasive treatment.

patients with radiologically early stage lung cancer who are candidates for sbrt will be enrolled in this study. prior to enrollment, patients are required to be evaluated by an experienced thoracic surgeon, radiation oncologist or medical oncologist to determine operability. patients will udergo computed tomography (ct) and positron emission tomography (pet) prior to ebus- tbna. ebus-tbna will be performed at the interventional thoracic surgery suite (itss) located at toronto general hospital by a thoracic surgeon. the procedure will be performed under local anesthesia with conscious sedation. mediastinal as well as hilar lymph nodes will be assessed by ebus-tbna. the result of pathological diagnosis using ebus-tbna will be compared with the result of radiological staging (ct and pet-ct). patients who are negative for mediastinal lymph node metastasis by ebus-tbna will undergo sbrt. in addition, the treatment outcome will be evaluated based on the clinical chart review.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. patients with confirmed lung cancer who require ebus-tbna as part of their staging investigations of the mediastinum and hilum prior to sbrt 3. performance status score (who/ecog) of 0-2. 4. cytological or histological proof of non-small cell cancer 5. stage t1-2 disease, with no evidence of distant metastasis 6. patients are screened by both computed tomography (ct) and positron emission tomography (pet) 7. medically inoperable for surgical resection 8. patients who refused surgery exclusion criteria: 1. patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy 2. active systemic, pulmonary, or pericardial infection 3. patients who are pregnant or lactating 4. patients with plans to receive conventional radiotherapy, chemotherapy, biological therapy, vaccine therapy, or surgery as treatment (except at disease progression). 5. inability to give informed consent
six month study to evaluate the safety and effectiveness of the intranasal lacrimal neurostimulator

Conditions: Dry Eye Syndromes; Keratoconjunctivitis Sicca

Summary: in this study, the safety and effectiveness of the oculeve intranasal lacrimal neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.

this is a prospective, single-arm, multicenter, open-label clinical trial in which participants will use the oculeve intranasal lacrimal neurostimulator to stimulate tear production for 180 days. participants will have a screening visit within 60 days prior to the initial device application. device application will be initiated at day 0, at which time participants will receive training on the proper use of the device. participants will receive follow-up visits at days 7, 30, 90 and 180.

Eligibility criteria:
inclusion criteria: * subjects with moderate to severe dry eye disease * literate, able to speak english or spanish, and able to complete questionnaires independently * willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol exclusion criteria: * chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the investigator, may lead to clinically significant increased bleeding * nasal or sinus surgery (including history of application of nasal cautery) or significant trauma * cardiac demand pacemaker, implanted defibrillator or other implanted electronic device * diagnosis of epilepsy * corneal transplant in either or both eyes * participation in any clinical trial with a new active substance or a new device within 30 days of the screening visit * women who are pregnant, planning a pregnancy, or nursing at the screening visit
the effect of stretching intensity on pain sensitivity

Conditions: Pain Threshold; Stretching; Pain Sensitivity; Range of Motion

Summary: the primary objective of this study is to determine the immediate efficiency of stretching intensity on regional and distant pain sensitivity in healthy subjects. it is hypothesized that the analgesic effect of stretching may be linked with the intensity of stretching in a dose-response relationship.


Eligibility criteria:
inclusion criteria: * healthy men and women aged 18-55 years are recruited. as part of the screening, volunteers will also be asked to indicate known medical issues or diseases. exclusion criteria: * participants are included if they have no known medical conditions such as; cognitive impairments, neurological, orthopaedic, or neuromuscular problems that might affect the somatosensory system or preclude stretching exercises or range of motion testing at the knee.
clinical trails of photoelectrochemical immunosensor for early diagnosis of acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the aim of this prospective randomized controlled clinical trial will evaluate the sensitivity, precision and effectiveness of photoelectrochemical immunosensor for early diagosis of acute myocardial infarction.


Eligibility criteria:
inclusion criteria: * age \> 18 years * symptoms of chest pain exclusion criteria: * patients who will undergo immediate pci pregnant * lactating women * patients with mental disorders * patients are using other experimental drugs; refusal to provide informed.
stroke telemedicine outpatient prevention program for blood pressure reduction

Conditions: Stroke Prevention; Blood Pressure; Telemedicine; Psychosocial Impairment

Summary: the purpose of this pilot trial is to compare post-stroke care blood pressure (bp) treatment using an interdisciplinary telehealth model \[called the stroke telemedicine outpatient program (stop) for blood pressure reduction\] to usual care in stroke patients at risk for uncontrolled bp. the intervention will address general and stroke-related factors associated with racial disparities in bp control. we will assess feasibility of implementation of the trial and will use the measures and outcomes assessed in the pilot to examine knowledge gaps.


Eligibility criteria:
inclusion criteria: * ischemic and hemorrhagic stroke patients * presence of at least one of the following high risk criteria: uninsured, medicaid payer status, small vessel ischemic stroke, hypertensive ich) * age ≥ 18; presence of hypertension (by clinical history or hospital bp ≥140/90 on two occasions) * plan to discharge home after stroke * ability to provide consent (patient or caregiver) * ability to communicate in english exclusion criteria: * modified rankin scale \> 4 at the time of enrollment (severe disability) * life expectancy \< 1 year or terminal illness, * egfr \< 30 at time of discharge * pregnancy * symptomatic flow limiting carotid stenosis without plan for intervention * urine toxicology positive for cocaine or methamphetamine or recent use * long-term bp goal ≥ 130/80 mmhg according to clinical team
comparison of gold fish exercises and cervico-thoracic postural correction training in patients with tmjd

Conditions: Temporomandibular Joint; Temporomandibular Joint Dysfunction

Summary: the aim of this randomized controlled trial is to determine the effect of gold fish exercises and cervico-thoracic postural correction training in patients with temporo-mandibular joint dysfunction to improve pain, rom and maximum mouth opening of jaw.

goldfish exercise works on the principle of pulsatile motion of goldfish in water \& thereby imitating the same motion for health benefits. it can be thought of stretching the fibrous bands, reducing tmj stiffness \& resulting in improvement of mouth opening. it would be beneficial to use this technique on daily basis and as far there are no contraindications of this exercise because it's done within the pain limits \& further progression depends on the mouth opening of the patient. posture can affect the three-dimensional movement of the jaw during opening which is seen most clearly in the slumped posture as reduced maximal mouth opening. while mouth opening and head extension are linked, there is variability in the amount of head extension when opening wide and the relationship between head extension and mouth opening is negated when opening in a slumped posture. this has implications for the association of neck dysfunction, posture, and temporo-mandibular joint disorder which should be explored further.

Eligibility criteria:
inclusion criteria: - age group 20-40 both males and females forward head posture and temporo-mandibular joint dysfunction for more than 3 months. pain provocation during neck movement, chewing and yawning; more than 5 on the visual analogue scale. exclusion criteria: * history of cervical spine injury or surgery * pain due to underlying condition i.e. neoplasm, vascular disease * infection, inflammation * erupting 3rd molar/dental origin * congenital condition of cervical spine or tmj

Keywords: temporomandibular joint dysfunction. gold fish exercises cervico-thoracic postural correction training
safety & efficacy study evaluating the combination of bevasiranib & lucentis therapy in wet amd

Conditions: Macular Degeneration

Summary: the purpose of this study is to compare the safety and effectiveness of bevasiranib given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of lucentis® (ranibizumab injection) compared to lucentis® given every 4 weeks to people with wet amd. patients will be assigned at random (like tossing a coin) to receive one of three treatments options for 104 weeks.


Eligibility criteria:
inclusion criteria: 1. patients must be age 50 years or older 2. patients must have predominantly classic, minimally classic or occult with no classic lesions secondary to age related macular degeneration. 3. the study eye must have etdrs best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 snellen equivalent). 4. patients must be willing and able to return for scheduled monthly follow-up visits for two-years. exclusion criteria: 1. prior pharmacologic treatment for amd in the study (patients can not have previously received avastin®/lucentis®, macugen®, or any other anti-vegf agents, steroid treatments, pdt, radiation treatment, or any experimental therapies for amd in the study eye) 2. any intraocular surgery of the study eye within 12 weeks of screening 3. previous posterior vitrectomy of the study eye 4. advanced glaucoma or intraocular pressure above 22 mm hg in the study eye despite treatment.

Keywords: amd macular degeneration bevasiranib cobalt study age related macular degeneration wet amd wet age related macular degeneration
efficacy and tolerability of saxagliptin add-on compared to uptitration of metformin in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the study will evaluate the efficacy and tolerability of saxagliptin compared to uptitration of metformin in patients with type 2 diabetes who have inadequate glycaemic control on a submaximal dose of metformin.


Eligibility criteria:
inclusion criteria: * provision of signed informed consent * established clinical diagnosis of type 2 diabetes. treatment with a stable dose of metformin monotherapy (1500-1700 mg/day) for at least 8 weeks prior to visit 1. * hba1c ≥7.0% and ≤10.0% exclusion criteria: * type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketonic coma. * renal impairment as defined by a creatinine clearance \<60 ml/min/1.73 m2 * individuals who, in the opinion of the investigator, in which participation in this study may pose a significant risk to the patient and could render the patient unable to successfully complete the study

Keywords: type 2 diabetes mellitus saxagliptin randomised double-blind
a research study, looking at how novomix® works in people with type 2 diabetes in local clinical practice in algeria

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information about how novomix® 30 works in real world adult population with type 2 diabetes. participants will get novomix® 30 as prescribed by the study doctor. the study will last for about 6-8 months. participants will be asked questions about their health and their diabetes treatment as part of their study doctor's appointment.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * the decision to initiate treatment with commercially available novomix® 30 has been made by the patient and the treating physician before and independently from the decision to include the patient in this study * male or female, greater than or equal to 19 years at the time of signing informed consent * diagnosed with type 2 diabetes and treated with basal insulin plus 1-3 bolus insulin injections per day for at least 24 weeks prior to informed consent * available and documented hba1c value less than or equal to 12 weeks prior to initiation of novomix® 30 treatment exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * participation in any clinical trial of an approved or non- approved investigational medicinal product within 24 weeks prior to initiation of novomix® 30 treatment. clinical trials do not include non-interventional studies * hypersensitivity to novomix® 30 or to any of the excipients * pregnancy or intention of becoming pregnant
tipifarnib and osimertinib in egfr-mutated non-small cell lung cancer

Conditions: NSCLC

Summary: this is a phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. the purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with osimertinib in patients with advanced/metastatic egfr-mutated non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years at the time of signing informed consent. * histologically or cytologically confirmed stage iiib (locally-advanced) or iv (metastatic) adenocarcinoma of the lung. * the tumor harbors an ex19del or ex21-l858r substitution (based on tumor tissue or plasma \[ctdna\] assessment). * treatment-naïve for locally advanced/metastatic egfr-mutated nsclc and osimertinib treatment-naïve for nsclc. * ecog performance score of 0 or 1 with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks. * measurable disease by recist v1.1 that meets the criteria for selection as a target lesion according to recist v1.1. * adequate organ function, as evidenced by the laboratory results. * other protocol-defined inclusion criteria may apply. exclusion criteria: * treatment with any of the following: 1. major surgery 2. radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug 3. medications or herbal supplements known to be potent inhibitors or inducers of cytochrome p450 (cyp) 3a4 or uridine 5'-diphospho (udp)-glucuronosyltransferase (ugt), or inhibitors of breast cancer resistance protein (bcrp). 4. investigational therapy within 2 weeks of cycle 1 day 1 5. concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug (excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and hormonal treatment for castration-sensitive prostate cancer) * spinal cord compression or symptomatic and unstable brain metastases requiring steroids over the last 4 weeks prior. * evidence of severe or uncontrolled systemic diseases. * refractory nausea and vomiting, chronic gastrointestinal (gi) diseases, inability to swallow the formulated product, or previous significant bowel resection. * clinically significant cardiovascular symptoms or disease. * received treatment for unstable angina within prior year, myocardial infarction within the prior 6 months, cerebro-vascular attack within the prior year, history of new york heart association grade iii or greater congestive heart failure, or current serious cardiac arrhythmia requiring medication except atrial fibrillation. * past medical history of interstitial lung disease (ild), drug induced ild, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ild. * other protocol-defined exclusion criteria may apply.

Keywords: egfr tipifarnib osimertinib nsclc locally advanced nsclc metastatic
the role of bathing additives in the treatment of pediatric atopic dermatitis

Conditions: Atopic Dermatitis; Eczema

Summary: to evaluate the efficacy of water bath, water + bleach, and water + vinegar (acetic acid) in the treatment of atopic dermatitis (eczema)

to perform a randomized controlled study to evaluate the efficacy of adding dilute acetic acid to the bath twice weekly on the eczema area and severity index (easi) score as compared to adding dilute bleach to the bath including a control arm in which no solution is added to the bath.

Eligibility criteria:
inclusion criteria: * currently reside in the usa * ability to comply with follow up visits at 2-4 months and at 6 months * come to the last follow-up at 6 months in the clinic * at least 5% body surface area (bsa) affected with ad exclusion criteria: * unclear diagnosis of atopic dermatitis * inability to comply with additive baths * inability to comply with follow-up visits * lack of residence in the united states

Keywords: atopic dermatitis eczema
g7 acetabular system vs. exceed abt acetabular system in tha

Conditions: Osteoarthritis Arthritis; Rheumatoid Arthritis

Summary: evaluate the safety and effectiveness of patients who received g7 acetabular system in conjunction with ceramic on ceramic articulation and taperloc complete microplasty stem compared to patients who received the exceed abt acetabular system with the same combination

this study will be a multi-center randomized controlled study. eligible patients will be randomly assigned to receive a combination of g7 acetabular system with coc articulation and taperloc complete microplasty stem or exceed abt acetabular system with coc articulation and taperloc complete microplasty stem. patient demographics, preoperative clinical outcomes, operative information, postoperative clinical outcome, radiographic assessment, incidence of squeaking, incidence of dislocation, implant survivorship and adverse events will be collected prospectively.

Eligibility criteria:
inclusion criteria: 1. non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis. 2. rheumatoid arthritis. 3. correction of functional deformity. 4. treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques. 5. revision of previously failed total hip arthroplasty. 6. age over 20 years old exclusion criteria: 1. uncooperative patient or patient with neurologic disorders who are incapable of following directions, 2. osteoporosis, 3. metabolic disorders which may impair bone formation, 4. osteomalacia, 5. distant foci of infections which may spread to the implant site, 6. rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram, and 7. vascular insufficiency, muscular atrophy, or neuromuscular disease.

Keywords: g7 acetabular system
single-operator versus dual-operator double-balloon endoscopy in patients with small-bowel disorders

Conditions: Small-Bowel Disorders

Summary: double-balloon endoscopy (dbe) is a new device that allows diagnosis and treatment throughout the entire small intestine. although the originally described method requires two operators, the investigators have recently developed a method to perform dbe by a single operator. the investigators here assessed the clinical usefulness of this one-person method in comparison to the conventional two-person dbe.


Eligibility criteria:
inclusion criteria: 1. suspected or known small-bowel disease 2. age: 16-70 exclusion criteria: 1. pregnancy 2. coagulation disorders 3. prior surgery of the small bowel and colon

Keywords: double-balloon endoscopy diagnostic yield